ALTO NEUROSCIENCE INC (ANRO) Stock Price, Forecast & Analysis
USA - NYSE:ANRO - US02157Q1094 - Common Stock
ANRO Key Statistics, Chart & Performance
The current stock price of ANRO is 13.4 USD. In the past month the price increased by 138.43%. In the past year, price increased by 196.46%.
ANRO Latest News, Press Relases and Analysis
ANRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.96 | 935.69B | ||
| JNJ | JOHNSON & JOHNSON | 18.67 | 466.81B | ||
| MRK | MERCK & CO. INC. | 10.32 | 227.17B | ||
| PFE | PFIZER INC | 7.97 | 145.04B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.43 | 99.17B | ||
| ZTS | ZOETIS INC | 18.95 | 53.23B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.48 | 22.72B | ||
| VTRS | VIATRIS INC | 4.81 | 13.06B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.81 | 11.36B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.78 | 8.33B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.63 | 4.09B |
Related stock screener links
About ANRO
Company Profile
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 76 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
Company Info
ALTO NEUROSCIENCE INC
650 Castro Street, Suite 450
Mountain View CALIFORNIA US
Employees: 76
Phone: 17732555012
ALTO NEUROSCIENCE INC / ANRO FAQ
What does ALTO NEUROSCIENCE INC do?
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 76 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
Can you provide the latest stock price for ALTO NEUROSCIENCE INC?
The current stock price of ANRO is 13.4 USD. The price increased by 5.18% in the last trading session.
Does ALTO NEUROSCIENCE INC pay dividends?
ANRO does not pay a dividend.
What is the ChartMill rating of ALTO NEUROSCIENCE INC stock?
ANRO has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists ANRO stock?
ANRO stock is listed on the New York Stock Exchange, Inc. exchange.
Should I buy ANRO stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ANRO.
What is ALTO NEUROSCIENCE INC worth?
ALTO NEUROSCIENCE INC (ANRO) has a market capitalization of 362.87M USD. This makes ANRO a Small Cap stock.
ANRO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ANRO. When comparing the yearly performance of all stocks, ANRO is one of the better performing stocks in the market, outperforming 99.08% of all stocks.
ANRO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANRO. The financial health of ANRO is average, but there are quite some concerns on its profitability.
ANRO Financial Highlights
Over the last trailing twelve months ANRO reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS increased by 13.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.08% | ||
| ROE | -52.55% | ||
| Debt/Equity | 0.18 |
ANRO Forecast & Estimates
15 analysts have analysed ANRO and the average price target is 19.09 USD. This implies a price increase of 42.45% is expected in the next year compared to the current price of 13.4.